The CATALYST trial is funded by UK Research and Innovation (UKRI), Medical Research Council (MRC).
Staff at the Cancer Research UK Clinical Trials Unit (CRCTU) who have helped support this trial are funded by a variety of different funders (including the UKRI and MRC). This includes Cancer Research UK (directly funded staff within CRCTU), Innovate UK (Midlands-Wales Advanced Therapy Treatment Centre), The Kennedy Trust (Arthritis Therapy Acceleration Program) and National Institute for Health Research (Birmingham Biomedical Research Centre).
Izana Bioscience Limited provides the drug Namilumab, which is one of the Investigational Medicinal Products (IMPs) used in the CATALYST trial.
Celltrion provided the drug Infliximab, which is one of the Investigational Medicinal Products (IMPs) that was previously used in the CATALYST trial.
CATALYST has been adopted onto the National Institute for Health Research (NIHR) Clinical Research Network (CRN) portfolio and has received Urgent Public Health research status.
Drugs that show promise from the data collected during the CATALYST trial will be considered for larger-scale testing by one of the current national, phase III, platform trials (RECOVERY or REMAP-CAP).